Comparative activity of telavancin and other antimicrobial agents against methicillin-resistant Staphylococcus aureus isolates collected from 1991 to 2006

Chemotherapy

Volumn 56, Issue 5, 2010, Pages 411-416

  Shams, Wael ^a,b   Walker, Elaine S ^a,b   Levy, Foster ^c   Reynolds, Scott A ^a   Peterson, Shalena M ^c   Sarubbi, Felix A ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b East Tennessee State University   (United States)

^c EAST TENNESSEE STATE UNIVERSITY   (United States)

Author keywords

Methicillin resistant Staphylococcus aureus; Minimal bactericidal concentration; Minimal inhibitory concentration; Telavancin

Indexed keywords

DAPTOMYCIN; LINEZOLID; TELAVANCIN; TIGECYCLINE; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BROTH DILUTION; CONTROLLED STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ACETAMIDES; AMINOGLYCOSIDES; ANTI-INFECTIVE AGENTS; DAPTOMYCIN; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; OXAZOLIDINONES; VANCOMYCIN;

EID: 77957769727     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000318057     Document Type: Article

References (34)

1. Allerberger F, Lechner A, Wechsler-Fördös A, Gareis R, on behalf of ABS International: Optimization of antibiotic use in hospitals - antimicrobial stewardship and the EU Project ABS International. Chemotherapy 2008; 54: 260-267
2. Soriano A, Marco F, Martinez JA, Pisos E, Almela M, Dimova VP, Alamo D, Ortega M, Lopez J, Mensa J: Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008; 46: 193-200. (Pubitemid 351269157)
3. Lodise TP, Graves J, Evans A, Graffunder E, Helmecke M, Lomaestro BM, Stellrecht K: Relationship between vancomycin MIC and failure among patients with methicillinresistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 2008; 52: 3315-3320.
4. Moise PA, Sakoulas G, Forrest A, Schentag JJ: Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2007; 51: 2582-2586. (Pubitemid 47047340)
5. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC, Eliopoulos GM: Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004; 42: 2398-2402. (Pubitemid 38747480)
6. Seifert H, Dowzicky MJ: A longitudinal analysis of antimicrobial susceptibility in clinical institutions in Germany as part of the Tigecycline Evaluation and Surveillance Trial (2004-2007). Chemotherapy 2009; 55: 241-252.
7. Krause KM, Renelli M, Difuntorum S, Wu TX, Debabov DV, Benton BM: In vitro activity of telavancin against resistant Gram-positive bacteria. Antimicrob Agents Chemother 2008; 52: 2647-2652. (Pubitemid 351915701)
8. Draghi DC, Benton BM, Krause KM, Thornsberry C, Pillar C, Sahm DF: In vitro activity of telavancin against recent Gram-positive clinical isolates: Results of the 2004-2005 Prospective European Surveillance Initiative. J Antimicrob Chemother 2008; 62: 116-121. (Pubitemid 351865882)
9. Leuthner KD, Cheung CM, Rybak MJ: Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus. J Antimicrob Chemother 2006; 58: 338-343.
10. Jansen WTM, Verel A, Verhoef J, Milatovic D: In vitro activity of telavancin against Gram-positive clinical isolates recently obtained in Europe. Antimicrob Agents Chemother 2007; 51: 3420-3424. (Pubitemid 350067570)
11. Saravolatz LD, Pawlak J, Johnson LB: Comparative activity of telavancin against isolates of community-associated methicillinresistant Staphylococcus aureus J Antimicrob Chemother 2007; 60: 406-409. (Pubitemid 47243894)
12. Stryjewski ME, Graham DR, Wilson SE, O'Riordan W, Young D, Lentnek A, Ross DP, Fowler VG, Hopkins A, Friedland HD, Barriere SL, Kitt MM, Corey GR: Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by Gram-positive organisms. Clin Infect Dis 2008; 46: 1683-1693. (Pubitemid 351706765)
13. Bassetti M, Mikulska M, Righi E, Nicolini L, Viscoli C: The role of telavancin in the treatment of MRSA infections in hospital. Expert Opin Investig Drugs 2009; 18: 521-529.
14. Hayden MK, Rezai KR, Hayes A, Lolans K, Quinn JP, Weinstein RA: Development of daptomycin resistance in vivo in methicillin- resistant Staphylococcus aureus J Clin Microbiol 2005; 43: 5285-5287. (Pubitemid 41484040)
15. Mangili, A, Bica I, Snydman DR, Hamer DH: Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2005; 40: 1058-1060. (Pubitemid 40418318)
16. Streit JM, Jones RN, Sader HS: Daptomycin activity and spectrum: A worldwide sample of 6737 clinical Gram-positive organisms. J Antimicrob Chemother 2004; 53: 669-674.
17. Johnson AP, Warner M, Livermore DM: Activity of linezolid against multi-resistant Gram-positive bacteria from diverse hospitals in the United Kingdom. J Antimicrob Chemother 2000; 45; 225-230. (Pubitemid 30095195)
18. Wise R, Andrews JM, Boswell FJ, Ashby JP: The in-vitro activity of linezolid (U-100766) and tentative breakpoints. J Antimicrob Chemother 1998; 42: 721-728. (Pubitemid 29008072)
19. Rybak MJ, Hershberger E, Moldovan T, Grucz RG: In vitro activities of daptomycin, vancomycin, linezolid, and quinupristindalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains. Antimicrob Agents Chemother 2000; 44: 1062-1066. (Pubitemid 30165292)
20. Cui L, Tominaga E, Neoh HM, Hiramatsu K: Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2006; 50: 1079-1082. (Pubitemid 43327815)
21. Clinical Laboratory Standards Institute: Performance Standards for Antimicrobial Susceptibility Testing: Sixteenth Informational Supplement M100-516. Clinical Laboratory Standards Institute, Wayne, PA, 2006.
22. Howden BP, Ward PB, Johnson PBR, Charles PGP, Grayson ML: Low-level vancomycin resistance in Staphylococcus aureus - an Australian perspective. Eur J Clin Microbiol Infect Dis 2005; 24: 100-108. (Pubitemid 40487377)
23. Wootton M, Howe RA, Hillman R, Walsh TR, Bennett PM, MacGowan AP: A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J Antimicrob Chemother 2001; 47: 399-403. (Pubitemid 32303403)
24. Holmes RL, Jorgensen JH: Inhibitory activities of 11 antimicrobial agents and bactericidal activities of vancomycin and daptomycin against invasive methicillin-resistant Staphylococcus aureus isolates obtained from 1999 through 2006. Antimicrob Agents Chemother 2008; 52: 757-760.
25. Lewis JS, Ellis MW: Approaches to serious methicillin-resistant Staphylococcus aureus infections with decreased susceptibility to vancomycin: Clinical significance and options for management. Curr Opin Infect Dis 2007; 20: 568-573.
26. Hatano K, Matsuzaki K, Sato Y, Kobayashi I, Yamaguchi K: In vitro antimicrobial activity of telavancin against methicillin-resistant Staphylococcus aureus clinical isolates from Japan. J Antibiot (Tokyo) 2007; 60: 709-712.
27. King A, Phillips I, Kaniga K: Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria. J Antimicrob Chemother 2004; 53: 797-803. (Pubitemid 38660281)
28. Hope R, Livermore DM, Brick G, Lillie M, Reynolds R: Non-susceptibility trends among staphylococci from bacteraemias in the UK and Ireland, 2001-2006. J Antimicrob Chemother 2008; 62(suppl 2):ii65-ii74.
29. Ho PL, Lo PY, Chow KH, Lau EH, Lai EL, Cheng VC, Kao RY: Vancomycin MIC creep in MRSA isolates from 1997 to 2008 in a healthcare region in Hong Kong. J Infect 2010; 60: 140-145.
30. Sader HS, Fey PD, Limaye AP, Madinger M, Pankey G, Rahal J, Rybak MJ, Snydman DR, Steed LL, Waites K, Jones RN: Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. medical centers from 2002 to 2006. Antimicrob Agents Chemother 2009; 53: 4127-4132.
31. Steinkraus G, White R, Friedrich L: Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin- susceptible clinical methicillinresistant S. aureus (MRSA) blood isolates from 2001-2005. J Antimicrob Chemother 2007; 60: 788-794. (Pubitemid 47434257)
32. Wang G, Hindler JF, Ward KW, Bruckner DA: Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol 2006; 44: 3883-3886. (Pubitemid 44737223)
33. Appelman MD, Citron DM: Efficacy of vancomycin and daptomycin against Staphylococcus aureus isolates collected over 29 years. Diagn Microbiol Infect Dis 2010; 66: 441-444.
34. Alós JI, Garcia-Cañas A, Garcia-Hierro P, Rodriquez-Salvanés F: Vancomycin MICs did not creep in S taphylococcus aureus isolates from 2002 to 2006 in a setting with low vancomycin usage. J Antimicrob Chemother 2008; 62: 773-775.